The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Mitigating Drug Shortages: FDA Officials Say Communication Is Crucial

Mitigating Drug Shortages: FDA Officials Say Communication Is Crucial

December 13, 2022 • By Thomas R. Collins

  • Tweet
  • Email
Print-Friendly Version / Save PDF

PHILADELPHIA—The most vital component of avoiding drug shortages is early communication, officials from the U.S. Food & Drug Administration (FDA) said in a session at ACR Convergence 2022 in November.

You Might Also Like
  • FDA Seeks Comments on Drug Shortages
  • Drug Shortages in U.S. Emergency Departments on the Rise
  • FDA Officials Speak Out: New Approvals & Safety Concerns Discussed
Also By This Author
  • Diagnosing & Managing Pulmonary & Kidney Manifestations in Lupus

“Early notification is key in order to prevent and mitigate shortages,” said Hyun Son, PharmD, a member of the Drug Shortage Staff with the FDA Center for Drug Evaluation and Research.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The session also included a review of the FDA’s “extrapolation of efficacy” approach to approving drugs for pediatric rheumatic diseases, in cases when there is enough similarity to adult care that a standard, randomized controlled trial isn’t necessary.

In her presentation, Dr. Son emphasized how important the FDA considers drug shortages to be.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“There’s always a sense of urgency when it comes to any drug shortages, but, ultimately, we want to maintain an availability while minimizing risk to the patients,” she said.

She said that if her office gets a notification from a manufacturer that it is having issues with a product, the FDA will look at the overall market and contact other suppliers of that product to see whether they can meet any increased demand.

There are steps within the power of the FDA, and steps that are not, she said. The FDA requires manufacturers to notify officials when there are supply disruptions, discontinuations or other issues that could harm supply, even if a given manufacturer has a relatively small share of the market. But the FDA can’t require a company to start making a drug, make more of a drug or mandate how a drug is distributed.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

What Can Be Done

The FDA can work with review divisions on expediting reviews.“As a last resort, we will exercise temporary importation of a product from outside the U.S.,” she said, as with triamcinolone hexacetonide injections during the current shortage.

In another recent example, there was a shortage of tocilizumab injections because of increased demand, and the FDA worked with manufacturers and the manufacturers were able to increase the supply. The shortage resolved in March 2022.

Asked about continuing issues with availability of triamcinolone hexacetonide injections, Dr. Son said, “If any institutions or hospitals or providers are having issues, you can definitely send us an email”—at [email protected]—“and we can forward all that information to Medexus,” the company authorized to import the drug. “We definitely would like to have an approval for a product instead of importing, but as of now, the imported product is the only product available for our U.S. patients.”

Pages: 1 2 | Single Page

Filed Under: ACR Convergence, Drug Updates, Legislation & Advocacy, Meeting Reports, Professional Topics Tagged With: ACR Convergence 2022, Drug shortage, FDA

You Might Also Like:
  • FDA Seeks Comments on Drug Shortages
  • Drug Shortages in U.S. Emergency Departments on the Rise
  • FDA Officials Speak Out: New Approvals & Safety Concerns Discussed
  • FDA Teams with Medical Companies in Puerto Rico to Tackle Shortages

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)